Biocon has appointed Arun Chandavarkar as chief operating officer. He was till now president -- operations and technology.
The company has announced that Rakesh Bamzai, who was earlier president-marketing pharma, will be the new president-marketing as Ajay Bhardwaj, the current incumbent, is leaving the organisation.
Chandravarkar will be actively involved in overseeing the day-to-day operations of the company, other than the subsidiaries Syngene and Clinigene. This will allow Kiran Mazumdar-Shaw to spend more time over strategy.
Chandavarkar has done masters and PhD in biochemical engineering from the Massachusetts Institute of Technology and has been working with Biocon since 1990.
Do you want to discuss stock tips? Do you know a hot one? Join the Stock Market Investments Discussion Group
